A systems biology approach to understanding the mechanisms of action of chinese herbs for treatment of cardiovascular disease

International Journal of Molecular Sciences

Volumn 13, Issue 10, 2012, Pages 13501-13520

  Li, Bohui ^a   Xu, Xue ^a   Wang, Xia ^a   Yu, Hua ^a   Li, Xiuxiu ^a   Tao, Weiyang ^a   Wang, Yonghua ^a   Yang, Ling ^b  

^a NORTHWEST A F UNIVERSITY   (China)

^b DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

Author keywords

Adme; Cardiovascular diseases; Systems pharmacology; Traditional chinese medicine

Indexed keywords

HERBACEOUS AGENT; CHUANGXIONG;

ARTICLE; CARDIOVASCULAR DISEASE; CHINESE MEDICINE; CONCENTRATION RESPONSE; CORYDALIS YANHUSUO; DALBERGIA ODORRIFERA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG SCREENING; LIGUSTICUM CHUANXIONG; MEDICINAL PLANT; PREDICTION; PROTEIN DETERMINATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; CARDIOVASCULAR DISEASES; CHEMISTRY; CORYDALIS; DALBERGIA; HUMAN; METABOLISM;

CARDIOVASCULAR DISEASES; CORYDALIS; DALBERGIA; DRUGS, CHINESE HERBAL; HUMANS; METABOLIC NETWORKS AND PATHWAYS; SYSTEMS BIOLOGY;

EID: 84870701834     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms131013501     Document Type: Article

References (58)

1. Knutsson, A.; Boggild, H. Shiftwork and cardiovascular disease: Review of disease mechanisms. Rev. Environ. Health 2000, 15, 359-372.
2. Xu, J.; Wu, H.Y. Chinese herbal medicine and acupuncture for the treatment of cardiovascular disease. J. Geriatr. Cardiol. 2009, 6, 56-61.
3. Cheung, F. TCM: Made in China. Nature 2011, 480, S82-S83.
4. Tachjian, A.; Maria, V.; Jahangir, A. Use of herbal products and potential interactions in patients with cardiovascular diseases. J. Am. Coll. Cardiol. 2010, 55, 515-525.
5. Ran, X.; Ma, L.; Peng, C.; Zhang, H.; Qin, L.-P. Ligusticum chuanxiong Hort: A review of chemistry and pharmacology. Pharm. Biol. 2011, 49, 1180-1189.
6. Liang, M.-J.; He, L.-C.; Yang, G.-D. Screening, analysis and in vitro vasodilatation of effective components from Ligusticum chuanxiong. Life Sci. 2005, 78, 128-133.
7. Tao, Y.; Wang, Y. Bioactive sesquiterpenes isolated from the essential oil of Dalbergia odorifera T. Chen. Fitoterapia 2010, 81, 393-396.
8. Steimle, A.E.; Lange, R.A.; Hillis, L.D. Antiplatelet therapy for ischemic heart disease. N. Engl. J. Med. 2004, 350, 2101-2102.
9. Liu, J.L.; Liu, H. The protective effects of dl-tetrahydropalmatine on isolated rat heart against ischemic/reperfusion damage exacerbated by extrinsic radical generating system. Zhongguo Yaoxue Zazhi 1994, 29, 462-464.
10. Ling, H.; Wu, L.; Li, L. Corydalis yanhusuo rhizoma extract reduces infarct size and improves heart function during myocardial ischemia/reperfusion by inhibiting apoptosis in rats. Phytother. Res. 2006, 20, 448-453.
11. Yuan, C.-S.; Mehendale, S.R.; Wang, C.-Z.; Aung, H.H.; Jiang, T.; Guan, X.; Shoyama, Y. Effects of Corydalis yanhusuo and Angelicae dahuricae on cold pressor-induced pain in humans: A controlled trial. J. Clin. Pharmacol. 2004, 44, 1323-1327.
12. Li, X.X.; Wang, J.N.; Yu, H.; Yang, H.J.; Xu, H.Y.; Tang, S.H.; Li, Y.; Wang, Y.H.; Yang, L.; Huang, L.Q.; et al. Investigation into the mechanisms of action of traditional Chinese medicine from chemical, genomic and pharmacological data in an integrated framework. PLoS One 2012, in press.
13. Yu, H.; Chen, J.X.; Xu, X.; Li, Y.; Zhao, H.H.; Fang, Y.P.; Li, X.X.; Zhou, W.; Wang, W.; Wang, Y.H. A Systematic prediction of multiple drug-target interactions from chemical, genomic and pharmacological data. PLoS One 2012, in press.
14. Chan, L.M.S.; Lowes, S.; Hirst, B.H. The ABCs of drug transport in intestine and liver: Efflux proteins limiting drug absorption and bioavailability. Eur. J. Pharm. Sci. 2004, 21, 25-51.
15. Yan, R.; Ko, N.L.; Li, S.L.; Tam, Y.K.; Lin, G. Pharmacokinetics and metabolism of ligustilide, a major bioactive component in Rhizoma chuanxiong, in the rat. Drug Metab. Dispos. 2008, 36, 400-408.
16. Ko, W.C. A newly isolated antispasmodic butylidenephthahde. Jpn. J. Pharmacol. 1980, 30, 85-91.
17. Wei, Y.; Hu, J.; Li, H.; Liu, J.G. Preparative isolation and purification of senkyunolide-I, senkyunolide-H and ferulic acid from Rhizoma chuanxiong using counter-current chromatography. J. Sep. Sci. 2011, 34, 3426-3432.
18. Che, M.T.; Wen, Y.C.; Wun, C.K.; Ouyang, C.H. Antiplatelet effect of butylidenephthalide. Biochim. Biophys. Acta Gen. Subj. 1987, 924, 375-382.
19. Ozaki, Y.; Sekita, S.; Harada, M. Centrally acting muscle relaxant effect of phthalides (ligustilide, cnidilide and senkyunolide) obtained from Cnidium officinale Makino. Yakugaku Zasshi 1989, 109, 402-406.
20. Jasicka-Misiak, I.; Lipok, J.; Nowakowska, E.M.; Wieczorek, P.P.; Mlynarz, P.; Kafarski, P. Antifungal activity of the carrot seed oil and its major sesquiterpene compounds. Z. Naturforsch. C J. Biosci. 2004, 59, 791-796.
21. Graf, E. Antioxidant potential of ferulic acid. Free Radic. Biol. Med. 1992, 13, 435-448.
22. Hou, Y.Z.; Yang, J.; Zhao, G.R.; Yuan, Y.J. Ferulic acid inhibits vascular smooth muscle cell proliferation induced by angiotensin II. Eur. J. Pharmacol. 2004, 499, 85-90.
23. Zhao, Z.H.; Moghadasian, M.H. Chemistry, natural sources, dietary intake and pharmacokinetic properties of ferulic acid: A review. Food Chem. 2008, 109, 691-702.
24. Jackson, S.P. The growing complexity of platelet aggregation. Blood 2007, 109, 5087-5095.
25. Yadav, V.R.; Prasad, S.; Sung, B.; Aggarwal, B.B. The role of chalcones in suppression of NF-κB-mediated inflammation and cancer. Int. Immunopharmacol. 2011, 11, 295-309.
26. Kim, Y.W.; Zhao, R.J.; Park, S.J.; Lee, J.R.; Cho, I.J.; Yang, C.H.; Kim, S.G.; Kim, S.C. Anti-inflammatory effects of liquiritigenin as a consequence of the inhibition of NF-κB-dependent iNOS and proinflammatory cytokines production. Br. J. Pharmacol. 2008, 154, 165-173.
27. Yu, X.L.; Wang, W.; Yang, M. Antioxidant activities of compounds isolated from Dalbergia odorifera T. Chen and their inhibition effects on the decrease of glutathione level of rat lens induced by UV irradiation. Food Chem. 2007, 104, 715-720.
28. Lin, W.W.; Karin, M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 2007, 11 7, 1175-1183.
29. Aggarwal, B.B.; Shishodia, S.; Sandur, S.K.; Pandey, M.K.; Sethi, G. Inflammation and cancer: How hot is the link? Biochem. Pharmacol. 2006, 72, 1605-1621.
30. Ding, B.; Zhou, T.; Fan, G.; Hong, Z.; Wu, Y. Qualitative and quantitative determination of ten alkaloids in traditional Chinese medicine Corydalis yanhusuo W.T. Wang by LC-MS/MS and LC-DAD. J. Pharm. Biomed. Anal. 2007, 45, 219-226.
31. Khan, I.A.; Alam, S.S.; Haq, A.; Jabbar, A. Biochemistry of resistance in chickpea against wilt disease caused by Fusarium osxysporum F.SP. ciceris. Pak. J. Bot. 2005, 37, 97-104.
32. Maurya, S.; Srivastava, J.S.; Jha, R.N.; Panday, V.B.; Singh, U.P. Effect of tetrahydropalmatine, an alkaloid on spore germination of some fungi. Mycobiology 2001, 29, 142-144.
33. Kurahashi, K.; Fujiwara, M. Adrenergic neuron blocking action of dehydrocorydaline isolated from Corydalis bulbosa. Can. J. Physiol. Pharmacol. 1976, 54, 287-293.
34. Li, H.L.; Han, T.; Liu, R.H.; Zhang, C.; Chen, H.S.; Zhang, W.D. Alkaloids from Corydalis saxicola and their anti-hepatitis B virus activity. Chem. Biodivers. 2008, 5, 777-783.
35. Gray, G.A.; Webb, D.J. The endothelin system and its potential as a therapeutic target in cardiovascular disease. Pharmacol. Ther. 1996, 72, 109-148.
36. Douglas, S.A.; Ohlstein, E.H. Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc. Med. 2000, 10, 229-237.
37. Linsel-Nitschke, P.; Tall, A.R. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat. Rev. Drug Discov. 2005, 4, 193-205.
38. Moens, A.L.; Kass, D.A. Tetrahydrobiopterin and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 2439-2444.
39. Liu, P.Y.; Death, A.K.; Handelsman, D.J. Androgens and cardiovascular disease. Endocr. Rev. 2003, 24, 313-340.
40. Yusuf, S.; Sleight, P.; Pogue, J.; Bosch, J.; Davies, R.; Dagenais, G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 2000, 342, 145-153.
41. Sun, D.Z.; Xu, L.; Wei, P.K.; Liu, L.; He, J. Syndrome differentiation in traditional Chinese medicine and E-cadherin/ICAM-1 gene protein expression in gastric carcinoma. World J. Gastroenterol. 2007, 13, 4321-4327.
42. Hishikawa, K.; Nakaki, T.; Fujii, T. Connective tissue growth factor induces apoptosis via caspase 3 in cultured human aortic smooth muscle cells. Eur. J. Pharmacol. 2000, 392, 19-22.
43. Lee, K.H.; Itokawa, H.; Kozuka, M. Oriental Herbal Products: The Basis for Development of Dietary Supplements and New Medicines in the 21st Century. In Oriental Foods and Herbs; Ho, C.T., Lin, J.K., Zheng, Q.Y., Eds.; Oxford University Press: Washington, WA, USA, 2003; pp. 2-31.
44. Small, K.M.; Wagoner, L.E.; Levin, A.M.; Kardia, S.L.R.; Liggett, S.B. Synergistic polymorphisms of b1-and a 2C-adrenergic receptors and the risk of congestive heart failure. N. Engl. J. Med. 2002, 347, 1135-1142.
45. Kelly, H.B. Coronary artery disease in aviation. Routine examination of aircrew. J. R. Soc. Med. 1979, 72, 374-377.
46. Miles, E.A.; Zoubouli, P.; Calder, P.C. Differential anti-inflammatory effects of phenolic compounds from extra virgin olive oil identified in human whole blood cultures. Nutrition 2005, 21, 389-394.
47. Cheng, W.H.; Lu, P.J.; Ho, W.Y.; Tung, C.S.; Cheng, P.W.; Hsiao, M.; Tseng, C.J. Angiotensin II inhibits neuronal nitric oxide synthase activation through the ERK1/2-RSK signaling pathway to modulate central control of blood pressure. Circ. Res. 2010, 106, 788-795.
48. Grosser, T.; Fries, S.; FitzGerald, G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest. 2006, 11 6, 4-15.
49. Houslay, M.D.; Baillie, G.S.; Maurice, D.H. cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: A molecular toolbox for generating compartmentalized cAMP signaling. Circ. Res. 2007, 100, 950-966.
50. Xu, Q. Role of heat shock proteins in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2002, 22, 1547-1559.
51. Atlas, S.A. The renin-angiotensin aldosterone system: Pathophysiological role and pharmacologic inhibition. J. Manag. Care Pharm. 2007, 13, 9-20.
52. Chou, M.T.; Wang, J.; Fujita, D.J. Src kinase becomes preferentially associated with the VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells. BMC Biochem. 2002, 3, doi:10.1186/1471-2091-3-32.
53. Bouloumie, A.; Schini-Kerth, V.B.; Busse, R. Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells. Cardiovasc. Res. 1999, 41, 773-780.
54. Fontana, J.; Fulton, D.; Chen, Y.; Fairchild, T.A.; McCabe, T.J.; Fujita, N.; Tsuruo, T.; Sessa, W.C. Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase and NO release. Circ. Res. 2002, 90, 866-873.
55. Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform. Available online: http://tcmspnw.com/login_clearSession (accessed on 1 November 2011).
56. Xu, X.; Zhang, W.X.; Li, Y.; Huang, C.; Yu, H.; Wang, Y.H.; Duan, J.Y. In silico prediction of human oral bioavailability based on molecular properties integrated with metabolism. Int. J. Mol. Sci. 2012, 13, 6964-6982.
57. Cosconati, S.; Forli, S.; Perryman, A.L.; Harris, R.; Goodsell, D.S.; Olson, A.J. Virtual screening with autodock: Theory and practice. Expert Opin. Drug Discov. 2010, 5, 597-607.
58. Smoot, M.E.; Ono, K.; Ruscheinski, J.; Wang, P.L.; Ideker, T. Cytoscape 2.8: New features for data integration and network visualization. Bioinformatics 2011, 27, 431-432.